Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Sees Large Decline in Short Interest

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totalling 115,600 shares, a decrease of 57.0% from the March 31st total of 268,900 shares. Based on an average trading volume of 111,900 shares, the short-interest ratio is presently 1.0 days. Approximately 2.6% of the shares of the company are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Salarius Pharmaceuticals stock. Armistice Capital LLC boosted its position in shares of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) by 105.2% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 225,000 shares of the company’s stock after buying an additional 115,364 shares during the quarter. Armistice Capital LLC owned 5.71% of Salarius Pharmaceuticals worth $148,000 at the end of the most recent quarter. Institutional investors own 11.88% of the company’s stock.

Salarius Pharmaceuticals Price Performance

SLRX remained flat at $0.50 during trading on Friday. The company had a trading volume of 4,071 shares, compared to its average volume of 39,317. The business’s 50 day moving average price is $0.56 and its 200 day moving average price is $0.62. Salarius Pharmaceuticals has a 52-week low of $0.43 and a 52-week high of $2.31.

Salarius Pharmaceuticals (NASDAQ:SLRX) last issued its quarterly earnings data on Friday, March 22nd. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.79. As a group, research analysts anticipate that Salarius Pharmaceuticals will post -26.8 earnings per share for the current year.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.